斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 19 Population Aging and the Future of Health Policy

19 Population Aging and the Future of Health Policy Comprehension Questions Indicate whether the statement is true or false,and justify your answer.Be sure to state any additional assumptions you may need. 1.Population growth in the developed world is contributing to population ag- ing. FALSE.In order for a population to exactly maintain its size fro n genera tion to generation,each woman must give birth to about 2.1 children over her lifetime.This special fertility rate is often called the population replace- ment fertility rate.In the last few decades,the total fertility rate in the devel- oped world has fallen below that level.Higher fertility rates in developing countries are actually slowing the aging of the world population 2.Japan's population is not aging along with the rest of the developed world. FALSE.Japan is the one of the starkes st e xamples of a population rapidly going gray.Indeed,the proportion of elderly in the Japanese population will increase at a far faster rate than in any other industrialized nation.Projec- tions indicate that 27.3 percent of the Japanese population will be over 65 by 2025,the one of the highest rates in the developed world. 3.In a world of population decline,many national health systems are not sol- vent because they were predicated on the assumption of population growth. 1
19 Population Aging and the Future of Health Policy Comprehension Questions Indicate whether the statement is true or false, and justify your answer. Be sure to state any additional assumptions you may need. 1. Population growth in the developed world is contributing to population aging. FALSE. In order for a population to exactly maintain its size from generation to generation, each woman must give birth to about 2.1 children over her lifetime. This special fertility rate is often called the population replacement fertility rate. In the last few decades, the total fertility rate in the developed world has fallen below that level. Higher fertility rates in developing countries are actually slowing the aging of the world population. 2. Japan’s population is not aging along with the rest of the developed world. FALSE. Japan is the one of the starkest examples of a population rapidly going gray. Indeed, the proportion of elderly in the Japanese population will increase at a far faster rate than in any other industrialized nation. Projections indicate that 27.3 percent of the Japanese population will be over 65 by 2025, the one of the highest rates in the developed world. 3. In a world of population decline, many national health systems are not solvent because they were predicated on the assumption of population growth. 1

2 Health Economics Answer Key TRUE.Many of these health systems are predicated on a bedrock assump ed reas sonable up until the last f ever the twin forces of rising life expectancy an declining birthrates will bankrupt these programs unless they are reformed 4.In recent years,each years'Medicare tax receipts have been sufficient to cover that year's services on behalf of enrollees. FALSE.I007,Medicare Part A expenditures exceeded payroll tax collec tions for the first time,and the Medicare Trust Fund has been on the decline since then. 5.In the 1970s,researchers were worried that,while Americans were living longer than previous generations,they were actually less healthy during old age than before.This phenomenon is known as the "compression of morbid- ity." FALSE.This findi vidence agai compre ion of morbidity,which oc- curs when disability and illness are delayed until later in life 6.Reducing mortality from one disease necessarily increases the sum of the to- tal mortality risk from all other causes of death TRUE.The inevitable rise in mortality from other causes that results from a reduction in mortality from any one particular cause is known as the competing risks problem 7.If a costless drug were created that effectively cured a prevalent and deadly disease,health care expenditures would decrease. FALSE.For example,overall health care expenditures might rise as a con- sequence of a new magical cancer treatment,even if the treatment itself is basically costless.This might occur if the costs of caring for heart attacks and other competing risks are more expensive than caring for cancer 8.Disproportionate spending on end-of-life care is never clinically justifiable FALSE.Some end-of-life health care is wasteful or even prolongs the pain of a dying patient,but in many cases,disproportionate spending on EOL of a cancer. Bhattacharya,Hyde &Tu2013 2
2 | Health Economics Answer Key TRUE. Many of these health systems are predicated on a bedrock assumption of population growth, which seemed reasonable up until the last few decades. However the twin forces of rising life expectancy and declining birthrates will bankrupt these programs unless they are reformed. 4. In recent years, each years’ Medicare tax receipts have been sufficient to cover that year’s services on behalf of enrollees. FALSE. In 2007, Medicare Part A expenditures exceeded payroll tax collections for the first time, and the Medicare Trust Fund has been on the decline since then. 5. In the 1970s, researchers were worried that, while Americans were living longer than previous generations, they were actually less healthy during old age than before. This phenomenon is known as the “compression of morbidity.” FALSE. This finding is evidence against compression of morbidity, which occurs when disability and illness are delayed until later in life. 6. Reducing mortality from one disease necessarily increases the sum of the total mortality risk from all other causes of death. TRUE. The inevitable rise in mortality from other causes that results from a reduction in mortality from any one particular cause is known as the competingrisks problem. 7. If a costless drug were created that effectively cured a prevalent and deadly disease, health care expenditures would decrease. FALSE. For example, overall health care expenditures might rise as a consequence of a new magical cancer treatment, even if the treatment itself is basically costless. This might occur if the costs of caring for heart attacks and other competing risks are more expensive than caring for cancer. 8. Disproportionate spending on end-of-life care is never clinically justifiable. FALSE. Some end-of-life health care is wasteful or even prolongs the pain of a dying patient, but in many cases, disproportionate spending on EOL care is clinically justifiable, as in the case of emergency surgery for patients with badly clogged arteries or chemotherapy capable of arresting the spread of a cancer. c Bhattacharya, Hyde & Tu 2013 2

Chapter 19 Population Aging and the Future of Health Policy3 9.Advance directives allow patients to indicate their own preferences about EOL care,but they cannot be acted upon if a dying patient is too sick to com- municate with doctors. cate instructions for situations in which he can no longer communicate. 10.Aggressive natalist policies have reversed brth rate declines in most European countries. FALSE.Natalist policies have enjoyed limited success in France and Sweden, but most European countries still have very low birth rates. 3 Bhattacharya,Hyde &Tu013
Chapter 19| Population Aging and the Future of Health Policy | 3 9. Advance directives allow patients to indicate their own preferences about EOL care, but they cannot be acted upon if a dying patient is too sick to communicate with doctors. FALSE. An advance directive is a binding legal document that indicates a patient’s wishes regarding end-of-life care. The patient can specifically indicate instructions for situations in which he can no longer communicate. 10. Aggressive natalist policies have successfully reversed birth rate declines in most European countries. FALSE. Natalist policies have enjoyed limited success in France and Sweden, but most European countries still have very low birth rates. 3 c Bhattacharya, Hyde & Tu 2013
按次数下载不扣除下载券;
注册用户24小时内重复下载只扣除一次;
顺序:VIP每日次数-->可用次数-->下载券;
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 18 The American Model.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 17 The Bismarck Model - Social Health Insurance.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 16 The Beveridge Model - Nationalized Health Care.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 15 The Health Policy Conundrum.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 14 Health Technology Assessment.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 13 Technology and the Price of Health Care.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 12 Pharmaceuticals and the Economics of Innovation.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 11 Moral Hazard.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 10 Adverse Selection in Real Markets.pdf
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 4 4 Crime.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 4 20.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 4 18 Is the Common Law Efficient.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 4 13 Some Very Different Systems.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 4 11 Antitrust.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 3 28 Tort.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 3 23 Family Law.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 3 21 Contract.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 3 2 Going over the Midterm plus Coase on China.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 3 16 Intellectual Property.pptx
- 《法律经济学》课程PPT教学课件(法律的经济分析)经济学与法律的对话(大卫·弗里德曼)L&E 3 14 Property.pptx
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 2 Demand for Health Care.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 20 The Economics of Health Externalities.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 21 Economic Epidemiology.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 22 Obesity.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 23 Prospect Theory.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 24 Time Inconsistency and Health.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 3 Demand for Health:The Grossman Model.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 4 Socioeconomic Disparities in Health.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 5 The Labor Market for Physicians.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 6 The Hospital Industry.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 7 Demand for Insurance.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 8 Adverse Selection - Akerlof’s Market for Lemons.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(试卷习题,英文版)课后判断题及答案 Ch 9 Adverse Selection - The Rothschild-Stiglitz Model.pdf
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 01 WHY HEALTH ECONOMICS?.ppt
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 10 ADVERSE SELECTION IN REAL MARKETS.ppt
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 11 MORAL HAZARD.ppt
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 12 PHARMACEUTICALS AND THE ECONOMICS OF INNOVATION.ppt
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 13 TECHNOLOGY AND THE PRICE OF HEALTH CARE.ppt
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 14 HEALTH TECHNOLOGY ASSESSMENT.ppt
- 斯坦福卫生经济学教材(Health Economics)杰伊·巴塔查里亚《健康经济学》课程教学资源(PPT课件,英文版)Chapter 15 THE HEALTH POLICY CONUNDRUM.ppt